Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses

By Jang-Hwan Cho, James J. Collins, Wilson W. Wong. Cell, 2018

604 citations recorded by the source corpus.

SUMMARY T cells expressing chimeric antigen receptors (CARs) are promising cancer therapeutic agents, with the prospect of becoming the ultimate smart cancer therapeutics. To expand the capability of CAR T cells, here we present a split, universal, and programmable (SUPRA) CAR system that simultaneously encompasses multiple critical “upgrades”, such as the ability to switch targets without re-engineering the T cells, finely tune T cell activation strength, and sense and logically respond to multiple antigens. These features are useful to combat relapse, mitigate over-activation, and enhance specificity. We test our SUPRA system against two different tumor models to demonstrate its broad utility and humanize its components to minimize potential immunogenicity concerns. Furthermore, we extend the orthogonal SUPRA CAR system to regulate different T cell subsets independently, demonstrating a dually inducible CAR system. Together, these SUPRA CARs illustrate that multiple advanced logic and control features can be implemented into a single, integrated system.

Subfields: Biomedical Engineering, Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/75194d50e88a37a3534d253e9987e2a1088831da

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Biomedical Engineering

1. Christopher S. Hackett
2. S. Rafiq
3. R. Brentjens

In Immunology

1. Christopher S. Hackett
2. S. Rafiq
3. R. Brentjens

In Oncology

1. Christopher S. Hackett
2. S. Rafiq
3. R. Brentjens

Citations in the corpus

• Engineering strategies to overcome the current roadblocks in CAR T cell therapy (2019, methodology): “In the SUPRA (split, universal and programmable) CAR system 139 , leucine zipper motifs are used to match CARs (zipCAR) with free scFvs (zipFv), again enabling simultaneous targeting of multiple antigens as well as the inclusion of multiple antigen logic gates and attenuation of CAR T cell…”